Details of the Drug
General Information of Drug (ID: DMDYRNF)
| Drug Name |
2'-Monophosphoadenosine-5'-Diphosphate
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
2'-MONOPHOSPHOADENOSINE-5'-DIPHOSPHATE; adenosine 2'-(dihydrogen phosphate) 5'-(trihydrogen diphosphate); 2-Phospho-adenosine diphosphate; 1afl; AC1L4WBL; phosphoadenosine diphosphate; AC1Q6S1C; 2'P-ADP; SCHEMBL905455; 5'-Diphosphoadenosine 2'-phosphate; DB02363; Adenosine 2'-phosphoric acid 5'-diphosphoric acid; Adenosine 5'-(trihydrogen diphorphate), 2'-(dihydrogen phosphate); [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl phosphono hydrogen phosphate
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 507.18 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -5.7 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 17 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


